194 related articles for article (PubMed ID: 9341919)
1. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
Dickinson RP; Dack KN; Long CJ; Steele J
J Med Chem; 1997 Oct; 40(21):3442-52. PubMed ID: 9341919
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane modulating agents. 4. Design and synthesis of 3-(2-[[(4-chlorophenyl)sulfonyl]-amino]ethyl)benzenepropanoic acid derivatives as potent thromboxane receptor antagonists.
Dack KN; Dickinson RP; Long CJ; Steele J
Bioorg Med Chem Lett; 1998 Aug; 8(16):2061-6. PubMed ID: 9873486
[TBL] [Abstract][Full Text] [Related]
3. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids.
Main AJ; Bhagwat SS; Boswell C; Goldstein R; Gude C; Cohen DS; Furness P; Lee W; Louzan M
J Med Chem; 1992 Nov; 35(23):4366-72. PubMed ID: 1447737
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
Tubaro E; Belogi L; Mezzadri CM
Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
[TBL] [Abstract][Full Text] [Related]
7. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
[TBL] [Abstract][Full Text] [Related]
8. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.
Takeuchi K; Kohn TJ; True TA; Mais DE; Wikel JH; Utterback BG; Wyss VL; Jakubowski JA
J Med Chem; 1998 Dec; 41(27):5362-74. PubMed ID: 9876106
[TBL] [Abstract][Full Text] [Related]
9. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 5. Synthesis and evaluation of enantiomers of 8-[[(4-chlorophenyl)sulfonyl]amino]-4-(3-pyridinylalkyl)octanoic acid.
Bhagwat SS; Gude C; Cohen DS; Dotson R; Mathis J; Lee W; Furness P
J Med Chem; 1993 Jan; 36(2):205-10. PubMed ID: 8423593
[TBL] [Abstract][Full Text] [Related]
11. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors.
Cimetière B; Dubuffet T; Landras C; Descombes JJ; Simonet S; Verbeuren TJ; Lavielle G
Bioorg Med Chem Lett; 1998 Jun; 8(11):1381-6. PubMed ID: 9871770
[TBL] [Abstract][Full Text] [Related]
12. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
Bhagwat SS; Gude C; Boswell C; Contardo N; Cohen DS; Dotson R; Mathis J; Lee W; Furness P; Zoganas H
J Med Chem; 1992 Nov; 35(23):4373-83. PubMed ID: 1447738
[TBL] [Abstract][Full Text] [Related]
13. [Synthesis and platelet aggregation inhibitory activity of analogues of 4-([2-(1H-imidazol-1-yl)-1-(4-substituted-phenyl)ethoxy]methyl)benzoic acids].
Wu QY; Yang JQ
Yao Xue Xue Bao; 1991; 26(10):741-6. PubMed ID: 1823715
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
[TBL] [Abstract][Full Text] [Related]
15. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
[TBL] [Abstract][Full Text] [Related]
16. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 2. Synthesis and biological activity of 8-(benzenesulfonamido)-7-(3-pyridinyl)octaonic acid and related compounds.
Main AJ; Goldstein R; Cohen DS; Furness P; Lee W
J Med Chem; 1992 Nov; 35(23):4362-5. PubMed ID: 1447736
[TBL] [Abstract][Full Text] [Related]
17. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
20. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
